Fenofibrate Increases High-Density Lipoprotein and Sphingosine 1 Phosphate Concentrations Limiting Abdominal Aortic Aneurysm Progression in a Mouse Model
Smriti M Krishna, Sai Wang Seto, Joseph V Moxon, Catherine Rush, Philip J Walker, Paul E Norman, Jonathan Golledge
AMERICAN JOURNAL OF PATHOLOGY | ELSEVIER SCIENCE INC | Published : 2012
There are currently no acceptable treatments to limit progression of abdominal aortic aneurysm (AAA). Increased serum concentrations of high-density lipoprotein (HDL) are associated with reduced risk of developing an AAA. The present study aimed to assess the effects of fenofibrate on aortic dilatation in a mouse model of AAA. Male low-density lipoprotein receptor-deficient (Ldlr(-/-)) mice were maintained on a high-fat diet for 3 weeks followed by 6 weeks of oral administration of vehicle or fenofibrate. From 14 to 18 weeks of age, all mice were infused with angiotensin II (AngII). At 18 weeks of age, blood and aortas were collected for assessment of serum lipoproteins, aortic pathology, ao..View full abstract
Awarded by National Health and Medical Research Council, Australia
Supported by the National Health and Medical Research Council, Australia (540404). J.G. holds a Senior Clinical Research Fellowship from the Queensland government and a Practitioner's Fellowship from the National Health and Medical Research Council, Australia.